News
EVO
10.14
+5.19%
0.50
Earnings Scheduled For March 28, 2023
Benzinga · 1d ago
Evotec gets $50M upfront from Bristol Myers in pact to develop neuro disease drugs
Seeking Alpha · 1d ago
Evotec's Preliminary 2022 Operating Income Declines, Revenue Rises
Evotec's Preliminary 2022 Operating Income Declines, Revenue Rises
MT Newswires · 1d ago
Evotec Extends, Expands Strategic Neurodegeneration Partnership With Bristol Myers Squibb, Originally Signed In 2016
Benzinga · 1d ago
Earnings Preview For Evotec
Benzinga · 1d ago
Evotec gets $6.6M from Gates Foundation to develop short-regimen TB drugs
Seeking Alpha · 5d ago
Evotec Wins $6.6M Grant for Drug Discovery in Tuberculosis
Benzinga · 5d ago
Evotec Gets $6.6 Million Grant From Gates Foundation
Evotec Gets $6.6 Million Grant From Gates Foundation
MT Newswires · 5d ago
Evotec Announced Progress Within Its Partnership With Bristol Myers Squibb Relating To Building A Molecular Glue-based Pipeline. Performance And Program-based Achievements Trigger $75M To Evotec
Benzinga · 03/16 08:40
Evotec gets a €150M loan from European Investment Bank
Seeking Alpha · 02/10 08:38
Evotec Bags €150M Loan from European Investment Bank
Benzinga · 02/10 07:31
Evotec Gets $161.1 Million Loan From European Investment Bank to Support R&D, Equity Investments, Building New Facility in France
Evotec Gets $161.1 Million Loan From European Investment Bank to Support R&D, Equity Investments, Building New Facility in France
MT Newswires · 02/10 05:03
Evotec Expands Drug Discovery Partnership With Related Sciences
Evotec Expands Drug Discovery Partnership With Related Sciences
MT Newswires · 02/09 05:57
Evotec SE gets new finance chief
Seeking Alpha · 02/07 09:06
Evotec SE Named Industry Veteran Laetitia Rouxel as CFO Effective April 1; Former Finance Chief Enno Spillner Will Depart To Pursue Other Opportunities
Benzinga · 02/07 07:36
Evotec Names Laetitia Rouxel Finance Chief
Evotec Names Laetitia Rouxel Finance Chief
MT Newswires · 02/07 04:16
Analysts Conflicted on These Healthcare Names: Can-Fite BioPharma (CANF), CareDx (CDNA) and Evotec AG (EVO)
TipRanks · 01/27 11:20
HC Wainwright & Co. Reiterates Buy on Evotec, Maintains $12 Price Target
Benzinga · 01/27 11:08
--HC Wainwright Reiterates Evotec SE at Buy With $12 Price Target
--HC Wainwright Reiterates Evotec SE at Buy With $12 Price Target
MT Newswires · 01/27 10:55
Evotec stock rises on licensing deal with J&J to develop immune-based drugs
Seeking Alpha · 01/26 10:52
More
Webull provides a variety of real-time EVO stock news. You can receive the latest news about Evotec Ag through multiple platforms. This information may help you make smarter investment decisions.
About EVO
Evotec SE is a Germany-based drug discovery and development company. The company is engaged in development of new pharmaceutical products through research alliances and development partnerships with pharmaceutical and biotechnology companies, academic institutions, patient organizations and venture capital companies. The drug discovery solutions are provided in the form of fee-for-service work, integrated drug discovery alliances, development partnerships, licensing of drug candidates and consulting arrangements. Evotec SE operates in a number of areas, including neuroscience, diabetes and complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases and fibrosis. Its pipeline covers a range of therapeutic areas, such as CNS Insomnia, Chronic cough, immunology & inflammation, women’s health endometriosis, nephrology, dermatological diseases, fibrotic disease and antiviral, among others.